The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review

被引:108
作者
Dolan, Ross D. [1 ]
Laird, Barry J. A. [1 ]
Horgan, Paul G. [1 ]
McMillan, Donald C. [1 ]
机构
[1] Univ Glasgow, Acad Unit Surg, Sch Med, Glasgow Royal Infirm, Glasgow, Lanark, Scotland
关键词
Cancer; Randomised clinical trials; Systemic inflammation; Glasgow prognostic score; Neutrophil lymphocyte ratio; Overall survival; TO-LYMPHOCYTE RATIO; PANCREATIC-CANCER; EXPLORATORY ANALYSIS; COLORECTAL-CANCER; PHASE-II; NEUTROPHIL; CHEMOTHERAPY; GEMCITABINE; SCORE; CELL;
D O I
10.1016/j.critrevonc.2018.09.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognostic value of the systemic inflammatory response in cancer has been well established in observational studies. This review aims to examine and rationalise the evidence for the role of systemic inflammation based prognostic scores in randomised clinical trials. Method: An extensive literature review using targeted medical subject headings was carried out in the MEDLINE, EMBASE, and CDSR databases until January 2018. Titles were examined for relevance and after exclusions bibliographies were hand searched to identify additional trials. Results: There were 29 trials containing data on 37,020 patients presented in full paper form and 8 trials containing data on 3805 patients presented in abstract form. Most trials were published within the last three years. Seven trials containing data on 6044 patients were published in 2015. Eight trials containing data on 4384 patients were published in 2016. Twelve trials containing data on 27,228 patients were published in 2017. The majority of trials were in advanced inoperable cancer and colorectal cancer was the most common cancer type with 11 articles containing data on 27,909 patients. The GPS/mGPS was shown to have prognostic value in randomised clinical trials in NSCLC, oesophageal cancer, pancreatic cancer, prostate cancer and breast cancer. The NLR/dNLR was shown to have prognostic value in randomised clinical trials in nasopharyngeal cancer, oesophageal cancer, pancreatic cancer, biliary cancer, prostate cancer and multiple cancer types. Conclusion: The prognostic value of systemic inflammation based prognostic scores has been confirmed in multiple trials and should be incorporated into future prospective randomised clinical trials.
引用
收藏
页码:130 / 137
页数:8
相关论文
共 51 条
[1]  
[Anonymous], 2017, WHO | Cancer Fact Sheet
[2]  
ARGILES G, 2018, J CLIN ONCOL, V36, DOI DOI 10.1200/JC0.2018.36.4_SUPP1.744
[3]   Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score) [J].
Bigot, Frederic ;
Castanon, Eduardo ;
Baldini, Capucine ;
Hollebecque, Antoine ;
Calmona, Alberto ;
Postel-Vinay, Sophie ;
Angevin, Eric ;
Armand, Jean-Pierre ;
Ribrag, Vincent ;
Aspeslagh, Sandrine ;
Varga, Andrea ;
Bahleda, Rastislav ;
Menis, Jessica ;
Gazzah, Anas ;
Michot, Jean-Marie ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Massard, Christophe .
EUROPEAN JOURNAL OF CANCER, 2017, 84 :212-218
[4]   The economics of cancer care in the UK [J].
Bosanquet, N ;
Sikora, K .
LANCET ONCOLOGY, 2004, 5 (09) :568-574
[5]   Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies [J].
Bruix, Jordi ;
Cheng, Ann-Lii ;
Meinhardt, Gerold ;
Nakajima, Keiko ;
De Sanctis, Yoriko ;
Llovet, Josep .
JOURNAL OF HEPATOLOGY, 2017, 67 (05) :999-1008
[6]   Development of a fully human T cell engaging bispecific antibody for the treatment of multiple myeloma. [J].
Buelow, Ben ;
Pham, Duy ;
Clarke, Starlynn ;
Aldred, Shelley Force ;
Dang, Kevin ;
Pratap, Payal ;
Ugamraj, Harshad ;
Harris, Katherine ;
Trinklein, Nathan ;
Schellenberger, Ute ;
Wiita, Arun ;
Van Schooten, Wim ;
Buelow, Ben .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7]   Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials [J].
Chua, Melvin Lee Kiang ;
Tan, Sze Huey ;
Kusumawidjaja, Grace ;
Shwe, Ma Than Than ;
Cheah, Shie Lee ;
Fong, Kam Weng ;
Soong, Yoke Lim ;
Wee, Joseph Tien Seng ;
Tan, Terence Wee Kiat .
EUROPEAN JOURNAL OF CANCER, 2016, 67 :119-129
[8]   Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer [J].
Chua, Wei ;
Clarke, Stephen J. ;
Charles, Kellie A. .
SUPPORTIVE CARE IN CANCER, 2012, 20 (08) :1869-1874
[9]  
Coleman N, 2017, ANN ONCOL, V28
[10]   Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients: The GOLFIG-2 Multicentric Open-label Randomized Phase III Trial [J].
Correale, Pierpaolo ;
Botta, Cirino ;
Rotundo, Maria S. ;
Guglielmo, Annamaria ;
Conca, Raffaele ;
Licchetta, Antonella ;
Pastina, Pierpaolo ;
Bestoso, Elena ;
Ciliberto, Domenico ;
Cusi, Maria G. ;
Fioravanti, Antonella ;
Guidelli, Giacomo M. ;
Bianco, Maria T. ;
Misso, Gabriella ;
Martino, Elodia ;
Caraglia, Michele ;
Tassone, Pierfrancesco ;
Mini, Enrico ;
Mantovani, Giovanni ;
Ridolfi, Ruggero ;
Pirtoli, Luigi ;
Tagliaferri, Pierosandro .
JOURNAL OF IMMUNOTHERAPY, 2014, 37 (01) :26-35